Mayo Clinic Study: Blood Test Predicts Cognitive Impairment Risk 5-10 Years Ahead
New blood tests can project an individual’s risk for cognitive impairment within five to 10 years, according to a Mayo Clinic study published in the journal JAMA Neurology.
By measuring levels of the phosphorylated tau 217 (p-tau217) protein, researchers identified biological changes linked to Alzheimer’s disease.
Key Clinical Takeaways:
- Blood biomarker analysis identifies pathology associated with Alzheimer’s before clinical symptoms manifest.
- The p-tau217 protein test assesses risk for cognitive decline within a five- to ten-year window.
- Current research emphasizes that detection does not equal diagnosis, as no treatment for asymptomatic disease is yet available.
The study addresses a major clinical gap: the inability of current diagnostic tools to reliably identify the biological precursors of neurodegeneration in the early stages. While Alzheimer’s disease is characterized by the accumulation of plaques and tangles within the brain, the ability to detect this pathology through a simple blood draw represents a shift toward highly scalable, less invasive monitoring of neurodegenerative risk.
Identifying Brain Pathology via Blood Biomarkers
Researchers examined blood samples from 2,178 cognitively unimpaired adults aged 60 to 90, integrating blood biomarker data with genetic and cognitive assessments. The study, published in JAMA Neurology, investigated whether p-tau217 levels could accurately estimate the likelihood that participants would develop cognitive deterioration within five to ten years.
The researchers also factored in age, gender, and the presence of the APOE ε4 genetic variant, which is known to be associated with Alzheimer’s risk.
Clifford Jack Jr., a Mayo Clinic neuroradiologist, explained the significance of the finding, stating, “The test tells you, just by taking a blood sample, whether someone has that pathology in the brain.” Jack Jr. added that higher levels of this pathology are linked to a greater likelihood of progressing from normal cognitive function to impairment.

Risk Profiles Vary by Age and Genetics
The analysis revealed that while the APOE ε4 variant had a modest association with risk, increasing age correlated with a higher probability of cognitive decline, even when accounting for biomarker levels. The data showed stark differences in risk based on age, even among individuals with similar elevated p-tau217 levels.
At the same elevated p-tau217 level, the risk of developing mild cognitive impairment over five years was estimated at 6% for a 65-year-old participant, compared to 37% for an 85-year-old participant, according to Fox News.
The following comparison illustrates the risk estimates based on elevated p-tau217 levels within the study population:
A blood biomarker for Alzheimer's disease may help estimate a cognitively healthy person's risk of developing mild cognitive impairment or dementia over the next five or 10 years, according to a new Mayo Clinic study. Learn more: https://t.co/px8SNAsJCW pic.twitter.com/AeIAxqGLEQ
Pathogenesis and Diagnostic Advancement
The goal of this research is to create a personalized risk assessment that moves beyond a simple positive or negative result for amyloid pathology, according to Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher.
Algeciras-Schimnich said that the objective is to offer an “estimation of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology.”
This approach provides a more scalable and minimally invasive diagnostic pathway compared to PET scans, which are currently used to measure amyloid burden, a hallmark of Alzheimer’s disease. The combination of biomarkers and glial cell response studies allows for the identification of individuals at higher risk of cognitive decline.

Limitations of the Current Risk Model
Despite the promise of the p-tau217 test, the research team stressed several limitations regarding its current clinical utility. The risk predictions were established using data from the Mayo Clinic Study of Aging, which is focused on a specific geographic area in southeast Minnesota.
Clifford Jack Jr. warned that the older population in this region does not represent the entire United States, and the findings must be replicated outside of that area, as reported by Fox News.
The research team maintained that the prediction model is not yet ready for routine screening in individuals who exhibit no cognitive symptoms. Jack Jr. clarified that there is currently no approved treatment for individuals who have the disease in the brain but remain asymptomatic. Because of this, he stated, “There is no treatment that’s been approved for people who are [asymptomatic] but have the disease in the brain.”
The study does not confirm that routine blood testing prevents dementia or improves clinical outcomes. Instead, it functions as a risk stratification tool that could become significant if preventive or disease-modifying treatments are developed and approved. Algeciras-Schimnich said that if preventive treatments become available, this type of predictive information could facilitate more informed conversations between patients and clinicians regarding the potential risks and benefits of intervention.
Clinical Application and Future Trajectory
As research continues, the focus remains on refining the risk model and identifying additional biological markers beyond p-tau217. The research team said that while the methods could be applied to other populations, the findings must be replicated outside of the region where they were initially observed.
“The older population in southeast Minnesota is not representative of the entire United States,” Jack Jr. told Fox News Digital.
Mayo Clinic traces its origins to 1864, when William Worrall Mayo settled in Rochester, Minnesota, and opened a medical practice that later evolved under his sons into the clinic that bears the family name.
Today it is a nonprofit academic medical center with campuses in Minnesota, Arizona, and Florida, employing more than 7,300 physicians and scientists. Its research funding exceeded $1 billion in 2022, and in that same year more than 1.3 million patients from all 50 U.S. states and 138 other countries were seen at its facilities.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Keep reading
- Updated German S3 Guideline Recommends First-Trimester Diabetes Risk Screening and Metformin as Insulin Alternative for Gestational Diabetes
- Bundeswehr Resumes Stabsfeldwebel Promotions in January 2027 With New Assignment Criteria
- World Atlas Ranks Great Lakes by Median Coldest-Day Water Temperature Over Five Years (archyde.com)
- Cleveland Clinic Tests Virtual Reality for Cancer Distress (newsdirectory3.com)